Liver transplant preservation injury represents a """"""""cold"""""""" ischemia/reperfusion (I/R) injury. Patients receiving livers with severe preservation injury exhibit significant increases in the length of ICU stay, infection, renal failure, biliary strictures, and allograft rejection. A profound arginine-deficient state occurs post-transplant due to arginase release from the injured liver graft. We believe arginine is critical for early hepatic protection, mediated in part by NO synthesis, and that arginine deficiency further contributes to ongoing liver graft injury. L-arginine supplementation does not result in increased circulating arginine levels and achieves only modest improvement in liver injury. Therefore, we hypothesize that inhibition of arginase will be required to enhance arginine availability and minimize damage resulting from liver preservation injury. This is a completely novel approach to combat organ injury; essentially nothing is known about the effects of arginase blockade in vivo. Preliminary data with injection of the arginase inhibitor, Nu-hydroxy-nor-L-arginine (nor-NOHA), showed that serum arginase activity was inhibited and circulating arginine levels were restored. This resulted in a significant decrease in liver enzyirie release and improvement in liver histology. In this proposal, we will pursue two aims to characterize arginine metabolism post-transplant and determine the effects of arginase blockade on liver cold I/R injury:
AIM I : TO DETERMINE WHETHER ENHANCING ARGININE AVAILABILITY THROUGH ARGINASE BLOCKADE PREVENTS LIVER TRANSPLANT ISCHEMIA/REPERFUSION INJURY. We will characterize arginine metabolism post-transplant and determine if arginine transport is modified during liver I/R injury. The effects of arginase blockade on serum and tissue arginine levels will be determined. The conditions that optimize arginine availability to maximize organ protection will be established. The potential adverse consequences of arginase inhibition on polyamine/proline synthesis, urea excretion, blood pressure, and alloimmurie response will be investigated.
AIM II : TO IDENTIFY THE MECHANISMS OF PROTECTION MEDIATED BY IMPROVING ARGININE AVAILABILITY ON LIVER GRAFT INJURY. We will determine if the beneficial effects of enhanced arginine availability are mediated by NO synthesis. The secondary mechanisms of tissue protection will be identified including the effects of enhanced arginine concentration on neutrophil infiltration, cytokine release, apoptosis, ultrastructural damage, hepatic blood flow, and HO-1 expression. The information gained will increase our understanding of the molecular pathophysiology of liver graft injury, and will provide completely new information regarding the in vivo effects of arginase blockade. We expect these findings to have broad implications far beyond transplant preservation injury that may be applicable to any form of liver injury resulting in hepatocellular arginase release and arginine depletion.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Research Project (R01)
Project #
1R01DK062313-01A2
Application #
6925763
Study Section
Surgery, Anesthesiology and Trauma Study Section (SAT)
Program Officer
Doo, Edward
Project Start
2005-06-01
Project End
2009-05-31
Budget Start
2005-06-01
Budget End
2006-05-31
Support Year
1
Fiscal Year
2005
Total Cost
$278,031
Indirect Cost
Name
University of Pittsburgh
Department
Surgery
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Yokota, Shinichiro; Yoshida, Osamu; Dou, Lei et al. (2015) IRF-1 promotes liver transplant ischemia/reperfusion injury via hepatocyte IL-15/IL-15R? production. J Immunol 194:6045-56
Klune, John R; Dhupar, Rajeev; Kimura, Shoko et al. (2012) Interferon regulatory factor-2 is protective against hepatic ischemia-reperfusion injury. Am J Physiol Gastrointest Liver Physiol 303:G666-73
Li, Peiyuan; Du, Qiang; Cao, Zongxian et al. (2012) Interferon-ýý induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1). Cancer Lett 314:213-22
Du, Qiang; Geller, David A (2010) Cross-Regulation Between Wnt and NF-?B Signaling Pathways. For Immunopathol Dis Therap 1:155-181
Ueki, Shinya; Dhupar, Rajeev; Cardinal, Jon et al. (2010) Critical role of interferon regulatory factor-1 in murine liver transplant ischemia reperfusion injury. Hepatology 51:1692-701
Park, Kyung Soo; Guo, Zhong; Shao, Lifang et al. (2009) A far-upstream Oct-1 motif regulates cytokine-induced transcription of the human inducible nitric oxide synthase gene. J Mol Biol 390:595-603
Du, Qiang; Zhang, Xinglu; Cardinal, Jon et al. (2009) Wnt/beta-catenin signaling regulates cytokine-induced human inducible nitric oxide synthase expression by inhibiting nuclear factor-kappaB activation in cancer cells. Cancer Res 69:3764-71
Ikeda, Atsushi; Ueki, Shinya; Nakao, Atsunori et al. (2009) Liver graft exposure to carbon monoxide during cold storage protects sinusoidal endothelial cells and ameliorates reperfusion injury in rats. Liver Transpl 15:1458-68
Kim, Kee-Hwan; Dhupar, Rajeev; Ueki, Shinya et al. (2009) Donor graft interferon regulatory factor-1 gene transfer worsens liver transplant ischemia/reperfusion injury. Surgery 146:181-9
Tomiyama, Koji; Ikeda, Atsushi; Ueki, Shinya et al. (2008) Inhibition of Kupffer cell-mediated early proinflammatory response with carbon monoxide in transplant-induced hepatic ischemia/reperfusion injury in rats. Hepatology 48:1608-20

Showing the most recent 10 out of 20 publications